A randomized phase III study comparing a new 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of efficacy and bleeding profiles

To compare contraceptive efficacy and bleeding profiles associated with use of the 13.5 mg (total content) levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol and 3 mg drospirenone combined oral contraceptive (COC) in younger women.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Source Type: research